Hikma Pharmaceuticals Resumes US Launch of Generic of GSK Asthma Treatment
21 Aprile 2021 - 8:46AM
Dow Jones News
By Anthony O. Goriainoff
Hikma Pharmaceuticals PLC said Wednesday that it has resumed the
launch of its generic version of GlaxoSmithKline PLC's asthma
treatment, Advair Diskus, in the U.S.
The FTSE 100 pharmaceutical company said the move followed the
Food and Drug Administration's approval of the amendment to its
abbreviated new drug application, submitted in January. The change
reflected enhanced packaging controls required to meet industry
standards adopted since the time of the initial submission.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
April 21, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024
